Disclaimer: Centuria Property Funds No.2 Limited ABN 38 133 363 185 AFSL 340304 (CPF2L) is the responsible entity for the Centuria Healthcare Property Fund (ARSN 638 821 360)(Fund) and has issued a Product Disclosure Statement (PDS) for the Fund. This information is general information only and does not take into account the objectives, financial situation or particular needs of any person. You should consider whether this information is appropriate for you and consult your financial or other professional adviser before investing. You should obtain and read a copy of the PDS relating to the Fund before making a decision to invest. CPF2L and its associates will receive fees in relation to an investment in the Fund as disclosed in the PDS. Investment in the Fund is subject to risk including possible delays in payment or loss of income and principal invested. CPF2L does not guarantee the performance of the Fund.
1. The target distribution rate is not a forecast, is predictive in nature and is subject to assumptions, risks and circumstances (both known and unknown) outside of the control of Centuria Property Funds No. 2 Limited, as responsible entity of the Fund. Actual returns may differ from the target return. Centuria Property Funds No. 2 Limited does not guarantee the performance of the Fund, the repayment of capital or any income or capital return. Should interest rates differ from forecast levels, distributions may be revised. Past performance is not indicative of future performance. Review the full historical performance.
2. Distributions will be paid if declared by Centuria Property Funds No.2 Limited (CPF2L) and will be subject to the terms set out in the PDS.
3. As at 05/08/2025
4. Performance is shown for informational purposes only. Past performance is not a reliable indicator of future performance. Performance fees may affect total return performance.
5. Assets as of 31 July 2025 following the successful divestment of 9 Charles Street, West Lakes SA on 16 July 2025.
6.vAs of 30 June 2025. Includes rental guarantees. Excludes Weststate Private Hospital.
7. The Core Property rating (assigned in November 2020) presented in this document has been prepared and issued by Core Property Research Pty Ltd (“Core Property”), which is an Authorised Representative ASIC number 1280479 of Core Property Research Holdings Pty Ltd (ACN 633 170 751, AFS License No. 518320) (Licensee), and trading as Core Property. Whilst the information contained in the report has been prepared with all reasonable care from sources that Core Property believes are reliable, no responsibility or liability is accepted by Core Property for any errors, omissions or misstatements however caused. Past performance information is for illustrative purposes only and is not indicative of future performance. The Core Property publication is not and should not be construed as, an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. Any opinion contained in the Report is unsolicited general information only. Neither Core Property nor the Participant is aware that any recipient intends to rely on this Report or of the manner in which a recipient intends to use it. To access the full report, please click here. The rating is subject to change without notice and Core Property assumes no obligation to update the report.
8. Lonsec ratings disclaimer: The Lonsec Rating (Centuria Healthcare Property Fund assigned Nov 2022) presented in this document is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445. The Rating is limited to “General Advice” (as defined in the Corporations Act 2001 (Cth)) and based solely on consideration of the investment merits of the financial product(s). Past performance information is for illustrative purposes only and is not indicative of future performance. It is not a recommendation to purchase, sell or hold Centuria product(s), and you should seek independent financial advice before investing in this product(s). The Rating is subject to change without notice and Lonsec assumes no obligation to update the relevant document(s) following publication. Lonsec receives a fee from the Fund Manager for researching the product(s) using comprehensive and objective criteria. For further information regarding Lonsec’s Ratings methodology, please refer to our website at: http://www.lonsecresearch.com.au/research-solutions/our-ratings
~ Inception date is 21 September 2020. Annualised total return figures are the sum of the annualised income return and the annualised capital return (each calculated on a standalone basis).
^ Redemptions are limited to the terms detailed in the PDS and are subject to CHPF’s liquidity policy